» Articles » PMID: 35976466

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

Abstract

Background: Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.

Methods: This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.

Results: Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.

Conclusions: We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.

Citing Articles

The value of preoperative RDW for post-pancreatectomy haemorrhage and surgical prognosis in patients with pancreatic cancer: a retrospective study.

Niu T, Wang Y, Lu L, Li J, Cheng T, Dai Y BMC Cancer. 2025; 25(1):437.

PMID: 40069621 PMC: 11895124. DOI: 10.1186/s12885-025-13849-y.


Surgical Outcomes in Stage IV Pancreatic Cancer with Liver Metastasis Current Evidence and Future Directions: A Systematic Review and Meta-Analysis of Surgical Resection.

Clements N, Gaskins J, Martin 2nd R Cancers (Basel). 2025; 17(4).

PMID: 40002281 PMC: 11853271. DOI: 10.3390/cancers17040688.


Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era?.

Svensson Di Giorgio S, Yoshino J, Morandi A, Scandavini C, Halimi A, Coppola A Hepatobiliary Surg Nutr. 2024; 13(6):1054-1057.

PMID: 39669078 PMC: 11634430. DOI: 10.21037/hbsn-24-603.


Performance of nutritional and inflammatory markers in patients with pancreatic cancer.

Lu J, Zhou L, Zhang S, Li J, Xu C World J Clin Oncol. 2024; 15(8):1021-1032.

PMID: 39193151 PMC: 11346065. DOI: 10.5306/wjco.v15.i8.1021.


Unveiling hidden outcomes in malignant gastric outlet obstruction research - insights from a "Pancreas 2000" review.

Vilas-Boas F, Rizzo G, de Ponthaud C, Robinson S, Gaujoux S, Capurso G World J Gastrointest Endosc. 2024; 16(8):451-461.

PMID: 39155997 PMC: 11325868. DOI: 10.4253/wjge.v16.i8.451.


References
1.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

2.
Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

3.
Shrikhande S, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I . Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006; 14(1):118-27. DOI: 10.1245/s10434-006-9131-8. View

4.
Antoniou E, Margonis G, Sasaki K, Andreatos N, Polychronidis G, Pawlik T . Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016; 86(12):973-977. DOI: 10.1111/ans.13738. View

5.
Buc E, Orry D, Antomarchi O, Gagniere J, Da Ines D, Pezet D . Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?. World J Surg Oncol. 2014; 12:347. PMC: 4289271. DOI: 10.1186/1477-7819-12-347. View